Items Tagged ‘Marginal zone lymphoma’

February 7th, 2017

Imbruvica® is approved by FDA for Marginal Zone Lymphoma


The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. These data were recently presented at the 58th Annual American Society of Hematology Meeting in December 2016. About Marginal Zone Lymphoma […]

View full entry

Tags: ibrutinib, imbruvica, Marginal zone lymphoma, News, nhl, Non-Hodgkin's Lymphoma, precision medicine